FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.
What's Your Reaction?
